The study conducted by Centre Antoine Lacassagne aims to identify predictive markers of resistance to sunitinib in mRCC patients, focusing on ELR+CXCL cytokines as potential therapeutic targets. Given the high unmet need for effective treatments in mRCC, the identification of these biomarkers could lead to improved patient stratification and treatment personalization, enhancing market opportunities for diagnostics and targeted therapies. The competitive landscape includes existing anti-angiogenic therapies and emerging immunotherapies. Companies developing companion diagnostics for mRCC may find strategic partnerships or acquisition opportunities in this space, particularly if the findings validate the clinical utility of ELR+CXCL cytokines.